Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business

Executive Summary

Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.

You may also be interested in...



Coronavirus Update: Pfizer/BioNTech Announce Positive Early Booster Data

The announcement comes amid signs of lagging bivalent booster uptake despite the possibility of a fall and winter surge. Novavax announced data from its combination coronavirus-influenza vaccine, but doubts remain as its approach’s competitiveness against mRNA vaccines. Moderna and Pfizer received EUAs for their bivalent vaccines in young children.

Pfizer’s Talzenna Takes On Top Dog Lynparza In Prostate Cancer

Top-line Phase III results for Talzenna/Xtandi showed improved PFS in mCRPC patients regardless of HRR mutation status, where AstraZeneca/Merck have developed fellow PARP inhibitor Lynparza.

Moderna’s Suit Against Pfizer/BioNTech Is About More Than Money

Moderna is seeking financial compensation for Comirnaty in its patent infringement suit, but it seems especially keen to assert IP rights over what could become an even more valuable platform technology.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel